KLOW Blend is a quad-peptide formulation of GHK-Cu, KPV, BPC-157, and TB-500 — adding KPV's melanocortin anti-inflammatory and gut-repair mechanisms to the Glow Blend's triple-peptide tissue repair profile.

Cosmetic Peptides

KLOW Blend (GHK-Cu / KPV / BPC-157 / TB-500)

The KLOW Blend is a quad-peptide research formulation combining GHK-Cu, KPV, BPC-157, and Thymosin Beta 4 (TB-500). It extends the Glow Blend's triple-peptide profile by adding KPV — a tripeptide alpha-MSH fragment with documented anti-inflammatory and gut-repair activity — to address a fourth mechanistic node across the inflammation, tissue repair, and skin biology research landscape. KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-melanocyte-stimulating hormone (α-MSH), an endogenous anti-inflammatory neuropeptide. KPV binds melanocortin receptors (MC1R and MC3R) and has been studied independently for anti-inflammatory effects in gut epithelial models, inflammatory bowel disease models in rodents, and dermal wound healing. Its mechanistic complementarity with BPC-157 — which also has gut-barrier protection research — creates a dual gut-repair coverage in the KLOW Blend: KPV via melanocortin receptor anti-inflammatory signaling, BPC-157 via NO-system angiogenesis and epithelial integrity mechanisms. GHK-Cu anchors the copper-peptide collagen synthesis and skin aging dimension; TB-500 covers the systemic cell migration and wound closure dimension. Together, the four components provide non-redundant mechanistic coverage across: (1) copper-peptide extracellular matrix biology, (2) melanocortin anti-inflammatory signaling, (3) localized connective tissue angiogenesis and gut repair, and (4) systemic actin-mediated cell migration and wound closure. For researchers studying gut-barrier biology, multi-pathway tissue repair, dermal inflammation, or combination peptide effects across inflammatory and regenerative mechanisms, the KLOW Blend is a single-vial formulation covering four pharmacologically independent research dimensions. This listing is for laboratory and preclinical research purposes only. Not for human or veterinary use.

Product Information

Shipping & Returns

Research reference only

This product is listed for research reference and is not currently available for ordering. See live alternatives below or contact the team.

Notify me when available

Currently unavailable

This product is listed for research reference. It is not currently available for ordering. Live alternatives from the same research category are shown below.

Product definition

What is KLOW Blend (GHK-Cu / KPV / BPC-157 / TB-500)?

KLOW Blend is a quad-peptide formulation of GHK-Cu, KPV, BPC-157, and TB-500 — adding KPV's melanocortin anti-inflammatory and gut-repair mechanisms to the Glow Blend's triple-peptide tissue repair profile.

The KLOW Blend is a research formulation designed to extend the Glow Blend's triple-peptide coverage (GHK-Cu + BPC-157 + TB-500) by incorporating KPV — the C-terminal tripeptide of alpha-MSH with independent melanocortin receptor-mediated anti-inflammatory activity. KPV (Lys-Pro-Val) was identified as the pharmacologically active anti-inflammatory fragment of α-MSH, retaining the parent molecule's MC1R and MC3R binding activity with a smaller molecular footprint. In preclinical gut models, KPV has been studied for NF-κB pathway suppression in intestinal epithelial cells, reduced inflammatory cytokine production, and barrier function protection in colitis models. These gut-specific anti-inflammatory effects are mechanistically distinct from BPC-157's gut-barrier NO-system mechanism — providing two pharmacologically independent approaches to gut research in the same formulation. The full KLOW profile covers: GHK-Cu (dermal collagen, hair follicle, wound healing via copper co-factor and TGF-β), KPV (gut epithelial anti-inflammation, MC1R/MC3R signaling), BPC-157 (connective tissue angiogenesis, gut barrier integrity, NO-system), and TB-500 (systemic cell migration, cardiac repair, wound closure via actin regulation).

Research context

How is KLOW Blend (GHK-Cu / KPV / BPC-157 / TB-500) described in the research literature?

GHK-Cu: copper-peptide collagen synthesis via TGF-β/MMP modulation. KPV: MC1R/MC3R anti-inflammatory signaling, gut epithelial protection. BPC-157: NO-system angiogenesis, connective tissue repair. TB-500: actin-G cell migration, systemic wound closure. Four pharmacologically independent receptor systems — non-redundant mechanistic coverage across inflammation, skin, gut, and systemic repair research.

Compound profile

Key facts about KLOW Blend (GHK-Cu / KPV / BPC-157 / TB-500)

Components
GHK-Cu + KPV + BPC-157 + Thymosin Beta 4 (TB-500)
KPV mechanism
MC1R/MC3R agonism — anti-inflammatory, gut epithelial protection
GHK-Cu mechanism
Copper peptide — collagen synthesis, skin repair
BPC-157 mechanism
NO-system angiogenesis, gut barrier, connective tissue
TB-500 mechanism
Actin-G regulation — systemic cell migration, wound closure
Research category
Gut-barrier biology, skin repair, multi-pathway inflammation and tissue research
Format
Lyophilized blend (single vial)
Storage
Lyophilized: −20°C. Reconstituted: 2–8°C, use within 30 days

Research areas

What research areas is KLOW Blend (GHK-Cu / KPV / BPC-157 / TB-500) associated with?

  • KPV adds MC1R/MC3R melanocortin anti-inflammatory signaling absent from the Glow Blend — gut epithelial protection research
  • Dual gut-repair coverage: KPV (melanocortin anti-inflammatory) + BPC-157 (NO-system barrier integrity) via distinct receptor systems
  • GHK-Cu covers copper-peptide collagen synthesis, skin aging, and extracellular matrix biology
  • TB-500 provides systemic cell migration and wound closure across cardiac, dermal, musculoskeletal tissue
  • Four pharmacologically independent receptor mechanisms — no redundancy across the KLOW component set
  • Single-vial convenience for complex multi-pathway tissue repair and inflammation research protocols

Research audience

Who researches KLOW Blend (GHK-Cu / KPV / BPC-157 / TB-500)?

The KLOW Blend is used by researchers in gut-barrier biology, inflammatory bowel disease preclinical research, skin inflammation, multi-pathway tissue repair, and combination peptide pharmacology. It is particularly suited to investigators studying both the anti-inflammatory and repair dimensions of gut and dermal tissue biology simultaneously.

Preclinical research overview

What does the preclinical literature say about KLOW Blend (GHK-Cu / KPV / BPC-157 / TB-500)?

The KLOW Blend was developed as an extended-coverage formulation building on the Glow Blend research rationale. The addition of KPV was driven by the recognition that the three-component Glow Blend lacked direct melanocortin receptor anti-inflammatory coverage — a mechanism with distinct documented effects in gut epithelial models that is not replicated by BPC-157's NO-system mechanism despite the functional overlap in the gut repair context. KPV's independent research profile includes studies in experimental colitis models (TNBS-induced, DSS-induced in rodents), where KPV administration reduced histological damage scores, decreased pro-inflammatory cytokine production, and preserved barrier function versus vehicle controls. These findings are mechanistically grounded in MC1R and MC3R expression in intestinal epithelial cells and macrophages — the same receptors that mediate α-MSH's systemic anti-inflammatory effects but with the accessibility of the short tripeptide fragment. For researchers studying the gut-skin axis, the KLOW Blend provides coverage of both tissue systems: KPV and BPC-157 for gut epithelial biology, GHK-Cu and TB-500 for dermal repair, with mechanistic overlap in the anti-inflammatory and wound-healing dimensions connecting the two tissue systems.

Common questions

Frequently asked about KLOW Blend (GHK-Cu / KPV / BPC-157 / TB-500)

What does KPV add that BPC-157 doesn't already cover for gut research?

BPC-157 operates through NO-system and VEGF angiogenesis pathways in gut models — promoting vascular repair and physical barrier integrity. KPV operates through MC1R/MC3R melanocortin receptor signaling to suppress NF-κB-driven inflammatory cytokine production in intestinal epithelial cells and macrophages. The anti-inflammatory pathway is pharmacologically distinct from BPC-157's angiogenesis mechanism. In colitis models, the two mechanisms address different aspects of disease pathology: BPC-157 the barrier integrity deficit, KPV the inflammatory amplification that drives mucosal damage.

How is the KLOW Blend different from the Glow Blend?

The Glow Blend contains GHK-Cu, BPC-157, and TB-500. The KLOW Blend adds KPV to that base. KPV adds: (1) melanocortin receptor anti-inflammatory mechanism, (2) specific gut epithelial research coverage absent from the Glow Blend. The KLOW Blend is the better choice when gut-barrier biology or inflammatory bowel models are part of the research design; the Glow Blend is the more focused choice for skin/dermal-only research protocols.

What is the evidence base for KPV in gut models?

KPV's gut research base includes in vitro studies in intestinal epithelial cell lines (NF-κB pathway suppression, cytokine reduction) and in vivo studies in TNBS-induced and DSS-induced colitis rodent models (reduced histological damage, preserved barrier function, lower inflammatory cytokine profiles). The mechanistic pathway involves MC1R/MC3R activation in both epithelial cells and macrophages within the intestinal wall. This research profile constitutes a meaningful preclinical evidence base though not at the same depth as BPC-157's gut literature.

Available now

Live alternatives from this research category

These products from the same research category are currently available for ordering.

Research Use Only

Sold for laboratory and research purposes only. Not approved for, nor intended for, human or veterinary consumption, diagnostic use, or therapeutic application. These products have not been evaluated by the Food and Drug Administration. Keep out of reach of children. For use by qualified researchers only.

Nothing on this page constitutes medical advice, a treatment recommendation, or a clinical protocol. Consult a qualified healthcare provider before making any health or treatment decisions.

By accessing this product page you confirm that you are a qualified researcher aged 18 or older and that you will use this product solely for lawful laboratory research purposes. View Research Use Policy